» Articles » PMID: 35246587

Human Infrapatellar Fat Pad Mesenchymal Stem Cells Show Immunomodulatory Exosomal Signatures

Overview
Journal Sci Rep
Specialty Science
Date 2022 Mar 5
PMID 35246587
Authors
Affiliations
Soon will be listed here.
Abstract

Within the human knee infrapatellar fat pad (IFP) and synovium, resident synoviocytes and macrophages contribute to the onset and progression of inflammatory joint diseases. Our hypothesis is that IFP-derived mesenchymal stem cells (IFP-MSC) robust immunomodulatory therapeutic effects are largely exerted via their exosomal (IFP-MSC EXOs) secretome by attenuating synoviocytes and macrophages pro-inflammatory activation. IFP-MSC EXOs showed distinct miRNA and protein immunomodulatory profiles. Reactome analysis of 24 miRNAs highly present in exosomes showed their involvement in the regulation of six gene groups, including immune system. Exosomes were enriched for immunomodulatory and reparative proteins that are involved in positive regulation of cell proliferation, response to stimulus, signal transduction, signal receptor activity, and protein phosphorylation. Stimulated synoviocytes or macrophages exposed to IFP-MSC EXOs demonstrated significantly reduced proliferation, altered inflammation-related molecular profiles, and reduced secretion of pro-inflammatory molecules compared to stimulated alone. In an acute synovial/IFP inflammation rat model, IFP-MSC EXOs therapeutic treatment resulted in robust macrophage polarization towards an anti-inflammatory therapeutic M2 phenotype within the synovium/IFP tissues. Based on these findings, we propose a viable cell-free alternative to MSC-based therapeutics as an alternative approach to treating synovitis and IFP fibrosis.

Citing Articles

Infrapatellar Fat Pad-Derived Non-Cellular Products in Therapy for Musculoskeletal Diseases: A Scoping Review.

Triangga A, Asmara W, Magetsari R, Bachtiar I, Fazatamma D, Saraswati P Orthop Rev (Pavia). 2024; 16:125841.

PMID: 39686964 PMC: 11646799. DOI: 10.52965/001c.125841.


The roles of regulatory-compliant media and inflammatory/oxytocin priming selection in enhancing human mesenchymal stem/stromal cell immunomodulatory properties.

Gardashli M, Baron M, Drohat P, Quintero D, Kaplan L, Szeto A Sci Rep. 2024; 14(1):29438.

PMID: 39604514 PMC: 11603324. DOI: 10.1038/s41598-024-80050-9.


The Use of Mesenchymal Stem/Stromal Cell-Derived Extracellular Vesicles in the Treatment of Osteoarthritis: Insights from Preclinical Studies.

Jones M, Jones E, Kouroupis D Bioengineering (Basel). 2024; 11(10).

PMID: 39451337 PMC: 11504680. DOI: 10.3390/bioengineering11100961.


Human mesenchymal stem/stromal cell-derived extracellular vesicle transport in meniscus fibrocartilage.

Schwartz G, Rana S, Jackson A, Lenero C, Best T, Kouroupis D J Orthop Res. 2024; 43(2):457-465.

PMID: 39396193 PMC: 11703673. DOI: 10.1002/jor.25993.


Evaluation of the therapeutic potential of infrapatellar fat pad adipose-derived stem cells and their secretome for regenerating knee articular cartilage in a rat model of osteoarthritis.

Dalir S, Meimandi Parizi A, Tanideh N, Kian M, Nowzari F, Iraji A Iran J Vet Res. 2024; 25(1):33-40.

PMID: 39156795 PMC: 11327642. DOI: 10.22099/IJVR.2024.47870.6959.


References
1.
Bondeson J, Blom A, Wainwright S, Hughes C, Caterson B, van den Berg W . The role of synovial macrophages and macrophage-produced mediators in driving inflammatory and destructive responses in osteoarthritis. Arthritis Rheum. 2010; 62(3):647-57. DOI: 10.1002/art.27290. View

2.
van Lent P, Blom A, Schelbergen R, Sloetjes A, Lafeber F, Lems W . Active involvement of alarmins S100A8 and S100A9 in the regulation of synovial activation and joint destruction during mouse and human osteoarthritis. Arthritis Rheum. 2011; 64(5):1466-76. DOI: 10.1002/art.34315. View

3.
Woo C, Kim H, Jung G, Jung Y, Lee K, Yun Y . Small extracellular vesicles from human adipose-derived stem cells attenuate cartilage degeneration. J Extracell Vesicles. 2020; 9(1):1735249. PMC: 7144299. DOI: 10.1080/20013078.2020.1735249. View

4.
Kilkenny C, Browne W, Cuthill I, Emerson M, Altman D . Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010; 8(6):e1000412. PMC: 2893951. DOI: 10.1371/journal.pbio.1000412. View

5.
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D . Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8(4):315-7. DOI: 10.1080/14653240600855905. View